Thursday, October 29, 2026
Data from SEC filings, checked daily
Public filings, plainly told
WallStPal · PDF guide
KALV Insider Trading and Fund Holdings (KalVista Pharmaceuticals, Inc.) · https://wallstpal.com/stock/kalv/ · saved 2026-10-29

About this page

Insider trades reported on SEC Form 4: when the people who run a company buy or sell its shares with their own money.

How to read it

Form 4
The form a company insider (officer, director or owner of more than 10%) must file with the SEC within two business days of buying or selling the company's shares.
Buy (P) and Sell (S)
Open-market purchases and sales. Gifts, option exercises and automatic tax withholding are left out because they say little about what the insider thinks.
Value
Shares times price, as reported on the filing.
10b5-1
A trade made under a plan set up in advance. Planned sales are common and usually say less than an unplanned purchase.
Late filing
A Form 4 filed more than two business days after the trade.
Vs. S&P 500
How the stock did after the trade minus how the overall market did in the same weeks.

A real example

In January 2016, when bank stocks were falling, JPMorgan Chase CEO Jamie Dimon bought 500,000 JPMorgan shares with his own money, worth about $26 million. His Form 4 made the purchase public within days, and investors read it as a strong sign of confidence.

Explain it like I'm 13

If the coach of a team bets his own allowance that his team will win, that tells you something. A Form 4 is the note a company boss must hand in whenever he buys or sells his own company's shares, so everyone can see it.

Data from public SEC filings and congressional reports. Information, not investment advice. Check every number against the filing linked on the page.

Summarize with AIChatGPTClaudePerplexityGoogle AIGrokCopilot
StockCIK 1348911

KalVista Pharmaceuticals, Inc. (KALV): Insider Trades and Fund Holdings

In the past 12 months, KalVista Pharmaceuticals, Inc. insiders reported no open-market purchases and 13 sales worth $1.75M; 0 of the sales were reported as made under a 10b5-1 trading plan.

0Insider buys, 12 months
$0Bought by insiders, 12 months
$1.75MSold by insiders, 12 months
0Tracked funds holding

Timeline: news and trades

Company filings (8-K), insider trades, notices of planned sales (Form 144), Congress trades and fund moves in the past year, newest first.

  1. Jun 30, 2026FundPoint72 Asset Management sold out in Q2 2026 (13F filed Aug 14, 2026)
  2. May 27, 2026Insider saleCHIEF DEVELOPMENT OFFICER Christopher Yea sold $905,225
  3. May 26, 2026Insider saleCHIEF MEDICAL OFFICER Paul K. Audhya sold $59,955
  4. May 26, 2026Insider saleCHIEF DEVELOPMENT OFFICER Christopher Yea sold $52,645
  5. May 26, 2026Insider saleChief Commercial Officer Nicole Sweeny sold $39,872
  6. May 22, 2026Insider saleCEO Benjamin L. Palleiko sold $292,646
  7. May 22, 2026Insider saleCHIEF MEDICAL OFFICER Paul K. Audhya sold $71,916
  8. May 22, 2026Insider saleCHIEF DEVELOPMENT OFFICER Christopher Yea sold $63,158
  9. May 22, 2026Insider saleChief Commercial Officer Nicole Sweeny sold $49,846
  10. May 22, 2026Insider saleCFO Brian Piekos sold $39,882
  11. May 18, 2026Insider saleCEO Benjamin L. Palleiko sold $30,212
  12. May 18, 2026Insider saleCHIEF DEVELOPMENT OFFICER Christopher Yea sold $29,650
  13. May 18, 2026Insider saleCHIEF MEDICAL OFFICER Paul K. Audhya sold $27,616
  14. May 12, 2026Insider saleCEO Benjamin L. Palleiko sold $88,731

Recent insider trades

Open-market purchases (code P) and sales (code S) from Form 4. Grants, option exercises and gifts are not shown. Latest filing: May 29, 2026.

Recent KALV insider trades
FiledTradedInsiderRoleTypeSharesPrice ($)ValueHoldingFiling
May 29May 27Christopher YeaCHIEF DEVELOPMENT OFFICERCHIEF DEVELOPMENT OFFICER▼ SELL33,80026.78$905K−13%Form 4 ↗
May 27May 26Paul K. AudhyaCHIEF MEDICAL OFFICERCHIEF MEDICAL OFFICER▼ SELL2,23926.78$60K−1.5%Form 4 ↗
May 27May 26Christopher YeaCHIEF DEVELOPMENT OFFICERCHIEF DEVELOPMENT OFFICER▼ SELL1,96626.78$53K−0.8%Form 4 ↗
May 27May 26Nicole SweenyChief Commercial OfficerChief Commercial Officer▼ SELL1,48926.78$40K−2.4%Form 4 ↗
May 26May 22Benjamin L. PalleikoCEOCEO▼ SELL10,92626.78$293K−2.2%Form 4 ↗
May 26May 22Paul K. AudhyaCHIEF MEDICAL OFFICERCHIEF MEDICAL OFFICER▼ SELL2,68526.78$72K−1.8%Form 4 ↗
May 26May 22Christopher YeaCHIEF DEVELOPMENT OFFICERCHIEF DEVELOPMENT OFFICER▼ SELL2,35826.78$63K−1.0%Form 4 ↗
May 26May 22Nicole SweenyChief Commercial OfficerChief Commercial Officer▼ SELL1,86126.78$50K−3.2%Form 4 ↗
May 26May 22Brian PiekosCFOCFO▼ SELL1,48926.78$40K−6.4%Form 4 ↗
May 19May 18Benjamin L. PalleikoCEOCEO▼ SELL1,12926.76$30K−0.2%Form 4 ↗
Source: SEC Form 4 filings, retrieved Oct 29, 2026. How we read filings
All 13 KALV insider trades →

Insiders who traded in the past year

InsiderRoleBuysBoughtSellsSoldLatest
Christopher YeaCHIEF DEVELOPMENT OFFICER0$04$1.05MMay 29, 2026
Paul K. AudhyaCHIEF MEDICAL OFFICER0$03$159KMay 27, 2026
Nicole SweenyChief Commercial Officer0$02$90KMay 27, 2026
Benjamin L. PalleikoCEO0$03$412KMay 26, 2026
Brian PiekosCFO0$01$40KMay 26, 2026
Filing quality

A All 13 insider trades reported on time. How it is graded

Tracked funds that report KALV

From each fund's latest 13F. Holdings are as of quarter end and are filed up to 45 days later.

FundQuarterSharesValue% of portfolioChange
Point72 Asset ManagementQ2 20260$00.00%▼ Sold out
Source: SEC Form 13F-HR filings, retrieved Oct 29, 2026. How we read filings

Reading these numbers

Insiders sell for many reasons: taxes, diversification, a house. Purchases with their own money are rarer and are usually read as more informative. A Form 4 is due within two business days of the trade. How to read a Form 4 →